Brokerages Set Arrowhead Pharmaceuticals, Inc. (ARWR) PT at $2.81

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the firm. Five analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $2.81.

A number of analysts have commented on ARWR shares. Chardan Capital cut their price target on shares of Arrowhead Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 10th. Cantor Fitzgerald reiterated a “buy” rating and issued a $15.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, November 10th. Jefferies Group LLC cut their price target on shares of Arrowhead Pharmaceuticals from $6.50 to $5.00 and set a “hold” rating for the company in a research note on Thursday, November 10th. William Blair cut shares of Arrowhead Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $12.00 to $2.00 in a research note on Wednesday, November 30th. Finally, Piper Jaffray Companies cut shares of Arrowhead Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $10.00 to $2.00 in a research note on Wednesday, November 30th.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at 1.97 on Monday. Arrowhead Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $8.22. The company’s 50-day moving average price is $1.84 and its 200-day moving average price is $4.64. The stock’s market cap is $146.90 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, February 6th. The company reported ($0.17) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.03. The business earned $4.37 million during the quarter, compared to analysts’ expectations of $13.24 million. Arrowhead Pharmaceuticals had a negative net margin of 1,663.58% and a negative return on equity of 89.07%. On average, equities analysts expect that Arrowhead Pharmaceuticals will post ($0.60) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by sleekmoney and is owned by of sleekmoney. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be accessed at http://sleekmoney.com/brokerages-set-arrowhead-pharmaceuticals-inc-arwr-pt-at-2-81/1658011.html.

Hedge funds have recently bought and sold shares of the company. RTW Investments LLC acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth approximately $8,208,000. Baker BROS. Advisors LP acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth approximately $13,649,000. Moors & Cabot Inc. raised its position in Arrowhead Pharmaceuticals by 11.0% in the third quarter. Moors & Cabot Inc. now owns 40,270 shares of the company’s stock worth $292,000 after buying an additional 4,000 shares in the last quarter. Hillhouse Capital Management Ltd. acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth approximately $4,983,000. Finally, RA Capital Management LLC acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth approximately $11,212,000. Institutional investors own 41.41% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

5 Day Chart for NASDAQ:ARWR

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/brokerages-set-arrowhead-pharmaceuticals-inc-arwr-pt-at-2-81/1658011.html

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *